retatrutide clinical trial saudi arabia New Phase 3 data just dropped ๐ Eli Lilly's reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Saudi Health Ministry detains gym
Description
It is not yet approved for routine prescribing, and the final licensed dose, availability, long-term safety profile and prescribing guidance are not yet confirmed
All current clinical trials use subcutaneous injection only
This should double Lilly's capacity once fully operational
GLP-1 2 1
SIRT1 enhances glucose tolerance by potentiating brown adipose tissue function
Cytokine-specific neurograms in the sensory Vagus nerve
